Evidence map›Paper›PMID 42838996›Full record

ArticleBritish journal of cancer2026

Integrated spatial and single-cell transcriptomics uncover IFI6⁺ regulatory T-cells and SPP1⁺ macrophages immunosuppressive niches in colorectal cancer.

Dominika Miroszewska, Shiyang Song, Víctor Urbiola-Salvador, Mariana Cázares Olivera, Agnieszka Jabłońska, Marika Bolcewicz, Leszek Kalinowski, Katarzyna Duzowska, Kinga Drężek-Chyła, Marek Zdrenka and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Dominika Miroszewska *Intercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, Gdańsk, Pomeranian, Poland.
Shiyang Song *Center for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine and Department of Thoracic Surgery of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Víctor Urbiola-Salvador *Intercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, Gdańsk, Pomeranian, Poland.
Mariana Cázares OliveraFaculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, North Ostrobothnia, Finland.
Agnieszka JabłońskaIntercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, Gdańsk, Pomeranian, Poland.
Marika BolcewiczDeparment of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland.
Leszek KalinowskiDeparment of Medical Laboratory Diagnostics-Fahrenheit Biobank BBMRI.pl, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland.
Katarzyna Duzowska3P-Medicine Laboratory, Medical University of Gdańsk, Gdańsk, Poland.
Kinga Drężek-Chyła3P-Medicine Laboratory, Medical University of Gdańsk, Gdańsk, Poland.
Marek ZdrenkaDepartment of Tumor Pathology and Pathomorphology, Oncology Center Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland.
Ewa ŚrutekDepartment of Tumor Pathology and Pathomorphology, Oncology Center Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland.
Łukasz SzylbergDepartment of Tumor Pathology and Pathomorphology, Oncology Center Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland.
Michał JankowskiDepartment of Oncological Surgery, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Toruń, Poland.
Dariusz BałaDepartment of Oncological Surgery, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Toruń, Poland.
Wojciech ZegarskiDepartment of Oncological Surgery, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Toruń, Poland.
Tomasz NowikiewiczDepartment of Oncological Surgery, Ludwik Rydygier's Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Toruń, Poland.ORCID http://orcid.org/0000-0002-6492-4427
Jan P Dumanski3P-Medicine Laboratory, Medical University of Gdańsk, Gdańsk, Poland.ORCID http://orcid.org/0000-0002-1489-1452
Bin LiCenter for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine and Department of Thoracic Surgery of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-7640-8884
Zhi ChenIntercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, Gdańsk, Pomeranian, Poland. zhi.chen@oulu.fi.ORCID http://orcid.org/0000-0002-4658-7463

Funding

Academy of Finland (Suomen Akatemia) decision number 325965Fundacja na rzecz Nauki Polskiej (Foundation for Polish Science) MAB/2018/6Gdański Uniwersytet Medyczny (Medical University of Gdańsk) Excellence Initiative-Research UniversityNarodowe Centrum Nauki (National Science Centre) 2018/30/Q/NZ6/00769
6 · The paper itself

Abstract

backgroundIn colorectal cancer (CRC), tumor-immune interactions are critical drivers of tumorigenesis, immune evasion, and therapeutic response. Therefore, a deeper spatially resolved understanding of these interactions is urgently needed.

methodsSpatial transcriptomics (ST) of CRC and matched normal samples was used to characterize cell populations and gene expression patterns associated with tumorigenesis and immune infiltration. An additional 41 publicly available ST slides, single-cell transcriptomics and bulk transcriptomics datasets from 472 and 617 CRC patients, respectively, were analyzed to validate the findings.

resultsCancer regions exhibited profound molecular alterations with increased oncogenic pathways, immunosuppressors, and tryptophan deprivation via KYNU-AHR axis, inducing the macrophage attractant CXCL5, contributing to immune evasion. In tumor boundaries, SPP1⁺ macrophages fostered an immunosuppressive microenvironment with regulatory T-cells (Tregs) recruited via CCL18-CCR8 and CCL22-CCR4. SIT1 emerged as a potential anti-tumor T-cells suppressor within tertiary lymphoid structures, suggesting a novel immune regulator. We also uncovered a previously uncharacterized population of tumor-infiltrating IFI6⁺ Tregs associated with unfavorable prognosis and therapy response, defined by elevated interferon-related genes and LGALS9, a potential immune checkpoint target.

conclusionThis study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.